 Weekly News | More » |
 |
Large Study Shows DFS Benefits of Oral Capecitabine Plus IV Oxaliplatin (XELOX) for Stage III Colon Cancer
OncologySTAT Editorial Team, 2009 Oct 8, B Bekiesz
EXPERT COMMENTARY
Long-term follow-up showed superior disease-free survival with adjuvant XELOX therapy in patients with stage III colon cancer.
|
Increased Recurrence Risk Seen in Younger Women with DCIS
Elsevier Global Medical News, 2009 Oct 7, S Boschert
Women younger than age 45 who were treated for DCIS were 68% more likely than older women to have a local recurrence.
|
Technique May Spare Biopsies in Early Breast Cancer
Elsevier Global Medical News, 2009 Oct 6, S Boschert
Adding ultrasound examination of axillary nodes and FNA of suspicious nodes avoided sentinel node biopsy and a second surgery.
|
Denosumab Shows Mixed Results in Bone Metastases Management
Elsevier Global Medical News, 2009 Oct 6, P Wendling
Denosumab was superior to zoledronic acid in the treatment of bone metastases in advanced breast cancer, but not in myeloma or selected solid tumors.
|
Aspirin Found to Prevent Cancer in Lynch Syndrome
Elsevier Global Medical News, 2009 Oct 6, P Wendling
The perseverance of researchers has led to the preliminary finding that aspirin helps prevent colon cancers in Lynch syndrome.
|
Vaccine Yield Mixed Results in Renal Cell Carcinoma
Elsevier Global Medical News, 2009 Oct 5, P Wendling
A phase III vaccine trial in RCC failed to meet its primary endpoint of improving OS, but an advantage was seen in a subset of good-prognosis patients.
|
Irinotecan Prolongs Survival in Progressive Metastatic Gastric Cancer
Elsevier Global Medical News, 2009 Oct 5, A Goodman
Irinotecan significantly prolonged overall survival compared with best supportive care in patients with advanced gastric cancer.
|
Link Between Diabetes Treatments, Cancer Is New Research Focus
Elsevier Global Medical News, 2009 Oct 5, ME Tucker
The question of whether insulin glargine—or insulin analogues in general—are associated with an increased risk for cancer remains open.
|
Pazopanib for Advanced Renal Cell Carcinoma Clears FDA Advisory Panel
Elsevier Global Medical News, 2009 Oct 5, E Mechcatie
ODAC unanimously voted that the benefit-to-risk profile of pazopanib was acceptable for advanced RCC but strongly recommended postmarketing surveillance for hepatotoxicity.
|
Panel Backs Long-Acting Interferon as Adjuvant Therapy for Melanoma
Elsevier Global Medical News, 2009 Oct 5, E Mechcatie
Peginterferon alfa-2b has a favorable risk-benefit ratio as an adjuvant treatment for stage III melanoma, an FDA advisory panel concluded.
|
Week in Review
